JP2021529814A5 - - Google Patents

Info

Publication number
JP2021529814A5
JP2021529814A5 JP2021500661A JP2021500661A JP2021529814A5 JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5 JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5
Authority
JP
Japan
Prior art keywords
substituted
cycloalkyl
heterocycloalkyl
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/055811 external-priority patent/WO2020012339A1/en
Publication of JP2021529814A publication Critical patent/JP2021529814A/ja
Publication of JP2021529814A5 publication Critical patent/JP2021529814A5/ja
Pending legal-status Critical Current

Links

JP2021500661A 2018-07-09 2019-07-08 化学化合物 Pending JP2021529814A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695384P 2018-07-09 2018-07-09
US62/695,384 2018-07-09
PCT/IB2019/055811 WO2020012339A1 (en) 2018-07-09 2019-07-08 Chemical compounds

Publications (2)

Publication Number Publication Date
JP2021529814A JP2021529814A (ja) 2021-11-04
JP2021529814A5 true JP2021529814A5 (cg-RX-API-DMAC7.html) 2022-07-15

Family

ID=67997654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500661A Pending JP2021529814A (ja) 2018-07-09 2019-07-08 化学化合物

Country Status (7)

Country Link
US (1) US20210253528A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820843A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021529814A (cg-RX-API-DMAC7.html)
CN (1) CN112424167A (cg-RX-API-DMAC7.html)
BR (1) BR112021000332A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105942A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020012339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
TW202545902A (zh) 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
PH12021552759A1 (en) * 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP1525185A1 (en) * 2002-07-24 2005-04-27 PTC Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007109107A2 (en) * 2006-03-17 2007-09-27 The Trustees Of Columbia University In The City Of New York Atf4 as a therapeutic target in alzheimers disease and other neurological disorders
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
HUE046660T2 (hu) * 2014-07-02 2020-03-30 Inflectis Bioscience O-alkil-benzilidén-guanidin-származékok és terápiás alkalmazás a rendellenes harmadlagos szerkezetû proteinek felhalmozódásával összefüggõ zavarok kezelésére
JP2017197433A (ja) * 2014-09-12 2017-11-02 石原産業株式会社 ニコチン酸エステル化合物、農園芸用殺菌剤及び植物病害の防除方法
TWI920577B (zh) * 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
RU2018145734A (ru) * 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
CN110730777A (zh) * 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
WO2019008506A1 (en) * 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada

Similar Documents

Publication Publication Date Title
JP2019521111A5 (cg-RX-API-DMAC7.html)
JP2019521109A5 (cg-RX-API-DMAC7.html)
RU2018146946A (ru) Химические соединения
RU2018145734A (ru) Химические соединения в качестве ингибиторов atf4 пути
JP7158382B2 (ja) C-kit阻害剤としてのアミノチアゾール化合物
JP2023518286A5 (cg-RX-API-DMAC7.html)
JP5978293B2 (ja) Namptを阻害するための新規な化合物および組成物
JP6227707B2 (ja) Mcl‐1を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。
AU2014222756B2 (en) Inhibitors of histone demethylases
US11932647B2 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
CN103261160A (zh) 用于抑制nampt的胍化合物和组合物
KR100737090B1 (ko) 축합 이미다졸륨 유도체
RU2018113430A (ru) Производные l-фенилпирролидин-2-она в качестве ингибиторов perk
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP2022504949A5 (cg-RX-API-DMAC7.html)
JP2021512059A5 (cg-RX-API-DMAC7.html)
US9255072B2 (en) Pyrazole compounds and thiazole compounds as protein kinases inhibitors
JPH11269146A (ja) 分化誘導剤
JP2017537948A5 (cg-RX-API-DMAC7.html)
US20150284347A1 (en) New benzene sulfonamide thiazole compounds
JP2020534373A5 (cg-RX-API-DMAC7.html)
JP2021529814A (ja) 化学化合物
TW202003487A (zh) 經取代的2,2'—聯嘧啶基化合物、其類似物及其使用方法
JP2025081626A (ja) ペンタミジンの類似体及びその使用
JP2023538159A5 (cg-RX-API-DMAC7.html)